Table 3.

Cost-effectiveness of introducing decentralized testing of suspected cholera cases, 2022–2035

Threshold	Total cost per averted case (US$)		OCV cost reduction per averted case (US$)	Test cost per averted case (US$)	OCV cost reduction per test dollar spent (US$)
	Clinical definition	Decentralized testing
1/10,000 per year	2,452 (2,153–2,707)	1,829 (1,653–2,017)	631 (509–731)	10 (9–11)	61 (52–69)
2/10,000 per year	1,841 (1,658–2,042)	1,272 (1,142–1,413)	587 (473–682)	13 (12–14)	45 (39–51)
10/10,000 per year	685 (603–780)	468 (405–543)	248 (176–326)	31 (25–39)	8 (6–9)

We report the median estimates and 95% PIs for total costs per averted cases and metrics that demonstrate tradeoffs in testing and OCV costs between clinical definition and decentralized testing settings. OCV cost reduction (due to systematic decentralized testing) per averted case is the difference between OCV cost per averted case in the decentralized testing and clinical definition scenarios. Test cost per averted case is the cost of testing in decentralized testing scenarios; no tests were performed in clinical definition scenarios. OCV cost reduction per test dollar spent is the ratio of OCV cost reduction per averted case and test cost per averted case.